Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 160

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 160
---
—— — — (182)(182)Balance as of December 31, 202236,956,345$4 $535,074 $(392,824)$(217)$142,037 Issuance of common stock in private placement, net of issuance costs of $7,7968,000,0001 202,203 — — 202,204 Issuance of common stock in at-the-market offerings, net of issuance costs of $518658,206— 14,480 — — 14,480 Issuance of common stock in connection with asset acquisition231,624— 5,188 — — 5,188 Issuance of common stock in connection with equity award plans760,226— 8,279 — — 8,279 Issuance of common stock in connection with employee stock purchase plan116,742— 2,191 — — 2,191 Stock-based compensation—— 35,845 — — 35,845 Net loss—— — (163,415)— (163,415)Other comprehensive income—— — — 1,861 1,861 Balance as of December 31, 202346,723,143$5 $803,260 $(556,239)$1,644 $248,670 Issuance of common stock in connection with equity award plans1,489,510— 15,059 — — 15,059 Issuance of common stock in connection with employee stock purchase plan125,443 2,640   2,640 Stock-based compensation—— 49,230 — — 49,230 Net loss—— — (87,942)— (87,942)Other comprehensive loss—— — — (2,017)(2,017)Balance as of December 31, 202448,338,096$5 $870,189 $(644,181)$(373)$225,640 

The accompanying notes are an integral part of these consolidated financial statements.

108

Table of Contents

Mirum Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(In thousands)

 Year Ended December 31, 202420232022Operating activitiesNet loss$(87,942)$(163,415)$(135,665)Reconciliation of net loss to net